Long term follow -up The patient’s primary oncologist will be sent a questionnaire regarding relapse yearly for 5 years after completion of study. The median TTP for stage IV breast cancer patients receiving trastuzumab is approxim ately 25 months. We will follow patients for OS for 5 years from enrollment. A comparison of OS to historical control will be made for patients with Stage IV breast cancer. 9. Evaluation and Management of Toxicity Subjects will be asked to report loca l reactions (to include pain, tenderness, erythema and induration) at the injection site and to report systemic reactions to include but not limited to fever, malaise, myalgia, nausea and headache. Monthly evaluation for toxicity will also include: CBC, U A, serum chemistries and a limited physical examination. Toxicity grading will be evaluated according to the NCI criteria; http://ctep.cancer.gov/forms/CTCAEv3.pdf and the Data Safety Monitoring Plan described in Appendix C. If a grade 3 or 4 toxicity related to the vaccination is observed in a subject, no further immunizations will be administered to that subject. Grade 2 allergy will not be defined as an excessive toxicity unless the reaction has lasted greater than 48 hours. If the toxicity observed is related to the immune response generated, a regimen of corticosteroids will be administered. The following dose schedule will be used: Day 1: Intravenous Solu -Medrol at 1 mg/kg Day 2: Intravenous Solu -Medrol at 1 mg/kg Day 3 -4: Prednisone at 30 mg BID PO q day Day 4 -5: Prednisone at 15 mg BID PO q day Day 5 -6: Prednisone at 10 mg BID PO q day Day 6 -7: Prednisone at 10 mg PO q day Day 8 -9: Prednisone at 5 mg PO q day All subjects will be monitored closely until the toxicity resolves. If a patient develops a toxicity that requires steroid treatment, no further vaccinations will be administered.